Pancreatic Cancer Research

ResearcherNational Institute of Biomedical Innovation, Health and NutritionActive in the last 2 years

Toru Otsuru

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7615-3124; OpenAlex author ID A5102751378. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 8

  1. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with firs… Co-author DOI 10.1007/s10147-025-02717-1↗
  4. Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.010↗
  5. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  6. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… Co-author DOI 10.1007/s00280-020-04110-3↗
  7. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Co-author DOI 10.1038/s41416-020-0781-2↗
  8. Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2… Co-author DOI 10.1111/cas.13918↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobumasa Mizuno · 3 shared papers, 2023–2026 · strength 0.56
  2. Akinori Asagi · 2 shared papers, 2025 · strength 0.45
  3. Yoshinori Ohno · 2 shared papers, 2025 · strength 0.45
  4. Mitsuhito Koizumi · 2 shared papers, 2025 · strength 0.45
  5. Ichinosuke Hyodo · 2 shared papers, 2025 · strength 0.45
  6. Yoichi Hiasa · 2 shared papers, 2025 · strength 0.45
  7. Masato Ozaka · 2 shared papers, 2026 · strength 0.43
  8. Chigusa Morizane · 2 shared papers, 2023–2026 · strength 0.36
  9. Hidetoshi Eguchi · 3 shared papers, 2019–2026 · strength 0.36
  10. Mitsuhito Sasaki · 2 shared papers, 2020–2026 · strength 0.33
  11. Naohiro Okano · 2 shared papers, 2023–2026 · strength 0.32
  12. Makoto Ueno · 2 shared papers, 2023–2026 · strength 0.32
  13. M Ueno · 1 shared paper, 2026 · strength 0.23
  14. Kenji Ikezawa · 1 shared paper, 2026 · strength 0.23
  15. Takeshi Terashima · 1 shared paper, 2026 · strength 0.23
  16. Yoshito Komatsu · 1 shared paper, 2026 · strength 0.23
  17. Hiroaki Nagano · 1 shared paper, 2026 · strength 0.23
  18. Hiroshi Ohyama · 1 shared paper, 2026 · strength 0.23
  19. Kumiko Umemoto · 2 shared papers, 2020–2023 · strength 0.22
  20. Masafumi Ikeda · 2 shared papers, 2020–2023 · strength 0.22
  21. Kaori Hino · 1 shared paper, 2025 · strength 0.20
  22. Teru Kumagi · 1 shared paper, 2025 · strength 0.20
  23. Taira Kuroda · 1 shared paper, 2025 · strength 0.20
  24. Yuki Numata · 1 shared paper, 2025 · strength 0.20
  25. Shingo Kagawa · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.